Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice (Q44070836)

29 November 2017

Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice (English)

1 reference

29 November 2017

1 reference

Atsushi Murai

1

1 reference

29 November 2017

Koji Iwamura

2

1 reference

29 November 2017

Masayasu Takada

3

1 reference

29 November 2017

Koichi Ogawa

4

1 reference

29 November 2017

Taichi Usui

5

1 reference

29 November 2017

Jun-ichi Okumura

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

71

1 reference

29 November 2017

12

1 reference

29 November 2017

1405-1415

1 reference

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Effect of acarbose (alpha-glucosidase inhibitor) on disaccharase activity in small intestine in KK-Ay and ddY mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Acarbose and nutrient intake in non-insulin dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

One-year acarbose treatment raises fasting serum acetate in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Acarbose-induced acute severe hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Acarbose-induced acute hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

A Bean α-Amylase Inhibitor Formulation (Starch Blocker) Is Ineffective in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Gastrointestinal and metabolic effects of amylase inhibition in diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Effect of a wheat amylase inhibitor on canine carbohydrate digestion, gastrointestinal function, and pancreatic growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Character of a wheat amylase inhibitor preparation and effects on fasting human pancreaticobiliary secretions and hormones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Chemo-enzymatic synthesis of galactosylmaltooligosaccharidonolactone as a substrate analogue inhibitor for mammalian alpha-amylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2901844-1

10.1016/S0024-3205(02)01844-1

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference